SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells all-stock agreement to acquire Lumentum is driving attention, with investors focused on potential shareholder dilution and the deals cost while others see a strategic boost in AI data-center optics and connectivity. The transaction remains subject to shareholder and regulatory approval.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned bond offering has focused attention on how it will fund its AI data-center expansion, with bears warning about leverage and bulls arguing the borrowing was already part of the disclosed financing plan. The sharp selloff has also fueled debate over whether the market is overreacting amid broader pressure on AI and tech stocks.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells agreed all-stock acquisition of Lumentum is driving attention, with traders debating its strategic fit in AI data-center optics versus concerns about the exchange ratio, dilution, and the long path to closing. Many LITE holders are frustrated that the shares are falling despite the announced premium, since the eventual value depends on Marvells share price.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Attention centers on third-party reports that POET optical engines appeared within Foxconns photonics ecosystem at its Tech Day, which bulls view as credibility for the companys AI-optics opportunity. Traders disagree on whether the display signals commercial progress, since it does not confirm production orders or scaled shipments; concerns about Marvells reported pursuit of Lumentum add debate over competition and supply-chain effects.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Shares have climbed to a fresh 52-week high ahead of Q3 results, with traders citing BRIUMVIs sales growth and the potential of its subcutaneous formulation. Buyout and short-squeeze speculation is prominent, but some investors stress that a deal is unconfirmed and focus instead on earnings and commercial execution.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD drew attention after a sharp selloff tied to DaVitas preliminary warning that DefenCath reimbursement could decline through 2027. Traders debate whether the outlook threatens adoption and revenue or is too uncertain to treat as company guidance, with some pointing to CMS reimbursement data and continued use while calling for clearer management updates.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsomes quarterly report showed strong product-revenue growth and a smaller-than-expected loss, with traders highlighting Auvelitys continued sales growth and a possible path toward cash-flow break-even. The reaction is divided: many called the results strong, while others questioned the stocks selloff and pointed to elevated expenses and the lack of quantified guidance.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention amid a sharp selloff in AI and optical-infrastructure stocks, with traders debating broader concerns about hyperscaler spending and the companys upcoming earnings. Dip buyers point to data-center optics demand, while bears worry about dilution, cash needs and customer concentration.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluences repeated fiscal 2026 guidance cut, attributed mainly to Houston manufacturing delays that are holding up deliveries, is driving bearish attention. Traders question managements execution and whether its backlog can translate into earnings, while some see the steep selloff as a buying opportunity and speculate about a short squeeze.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about pressure on Precigens PAPZIMEOS. Traders debate whether the rivals dosing approach will erode demand or whether PAPZIMEOSs commercial head start, established payer access and reported sales will help it maintain an advantage, with upcoming earnings also in focus.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$GALT Based on SEC filings we have good data on warrant and option shares potentially exercisable and we can expect will be exercised in the event of partnership. Others may have better, more exact number, but by my math, as it stands NOW, we would be at a total of 126 million shares (give or take) after any full dilution from outstanding warrants and options.  NFA. GLTA.

Jeffery Rachford

"Schuuultz!"

$GALT Jelly or someone with the knowledge to answer this question. Galectin Therapeutics (GALT) has a public float of approximately 46.93 million to 47.19 million shares.Key Metrics BreakdownPublic Float: ~47 million shares available for public trading.Insider / Restricted Shares: ~18.8 million shares held by insiders or institutions that are excluded from the public float.Short Interest Percentage: Roughly 16.76% to 28.74% of the float is currently sold short, depending on the reporting exchange.  How would Warrants play in to the price of each share if GALT were to be brought. Bo - said thank you.

StockTwits for iOS

Galectin Therapeutics Inc

Jim Sorvillo

StockTwits Web

 Based on SEC filings we have good data on warrant and option shares potentially exercisable and we can expect will be exercised in the event of partnership. Others may have better, more exact number, but by my math, as it stands NOW, we would be at a total of 126 million shares (give or take) after any full dilution from outstanding warrants and options.  NFA. GLTA.